Base de dados : MEDLINE
Pesquisa : D12.776.124.270.300 [Categoria DeCS]
Referências encontradas : 7701 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 771 ir para página                         

  1 / 7701 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29472180
[Au] Autor:Stubbs MJ; Mouyis M; Thomas M
[Ad] Endereço:University College London Hospital, London, UK m.stubbs@doctors.org.uk.
[Ti] Título:Deep vein thrombosis.
[So] Source:BMJ;360:k351, 2018 02 22.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Perna (Membro)/irrigação sanguínea
Trombose Venosa/diagnóstico
[Mh] Termos MeSH secundário: Anticoagulantes/uso terapêutico
Biomarcadores/análise
Produtos de Degradação da Fibrina e do Fibrinogênio/análise
Seres Humanos
Fatores de Risco
Ultrassonografia
Trombose Venosa/sangue
Trombose Venosa/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Biomarkers); 0 (Fibrin Fibrinogen Degradation Products); 0 (fibrin fragment D)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180224
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.k351


  2 / 7701 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29374925
[Au] Autor:Liu W; Chai JK
[Ad] Endereço:Burn Institute, the First Affiliated Hospital of PLA General Hospital, Beijing 100048, China.
[Ti] Título:[Influences of ulinastatin on acute lung injury and time phase changes of coagulation parameters in rats with burn-blast combined injuries].
[So] Source:Zhonghua Shao Shang Za Zhi;34(1):32-39, 2018 Jan 20.
[Is] ISSN:1009-2587
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To explore the influences of ulinastatin on acute lung injury and time phase changes of coagulation parameters in rats with severe burn-blast combined injuries. One hundred and ninety-two Sprague-Dawley rats were divided into pure burn-blast combined injury group, ulinastatin+ burn-blast combined injury group, and sham injury group according to the random number table, with 64 rats in each group. Two groups of rats with combined burn-blast injuries were inflicted with moderate blast injuries with the newly self-made explosive device. Then the rats were inflicted with 25% total body surface area full-thickness scald (hereinafter referred to as burn) on the back by immersing in 94 ℃ hot water for 12 s. Rats in sham injury group were sham injured on the back by immersing in 37 ℃ warm water for 12 s. Immediately after injury, rats in the three groups were intraperitoneally injected with Ringer's lactate solution (40 mL/kg), meanwhile rats in ulinastatin+ burn-blast combined injury group were intraperitoneally injected with ulinastatin (4×10(4)U/kg), once every 12 hours, until post injury hour (PIH) 72. Before injury, at PIH 3, 6, 12, 24, 48, 72, and on post injury day (PID) 7, 8 rats in each group were selected to harvest abdominal aortic blood samples to detect plasma levels of activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen, D-dimer, antithrombin Ⅲ (AT-Ⅲ), and α2-antiplasmin (α2-AP). At PIH 24, three rats in each group which were used in detection of coagulation parameters were sacrificed to observe lung injury. At PIH 72, three rats in each group were sacrificed for histopathological observation of lung. Data were processed with analysis of variance of factorial design and least-significant difference test. (1) Compared with those of rats in sham injury group, APTT of rats in pure burn-blast combined injury group significantly prolonged at PIH 72 and on PID 7 ( <0.05 or <0.01). PT significantly prolonged at PIH 3 and 72 and significantly shortened at PIH 6 ( <0.05 or <0.01) . Fibrinogen level significantly increased from PIH 12 to PID 7 ( <0.01). AT-Ⅲ level significantly decreased at PIH 6 and 12 ( <0.01), and α2-AP level significantly decreased at PIH 6 and significantly increased from PIH 24 to 72 ( <0.01). Compared with those of rats in pure burn-blast combined injury group, APTT of rats in ulinastatin+ burn-blast combined injury group significantly prolonged at PIH 3 and 6 ( <0.01) while PT significantly shortened at PIH 3, 12, and 72 ( <0.05 or <0.01). Fibrinogen level significantly decreased at PIH 6 and 12 and significantly increased at PIH 72 ( <0.05 or <0.01). AT-Ⅲ level significantly increased at PIH 3, 12, 48, and 72 ( <0.05 or <0.01), and α2-AP level significantly decreased from PIH 12 to 72 ( <0.05 or <0.01). D-dimer level of rats in sham injury group, pure burn-blast combined injury group, and ulinastatin+ burn-blast combined injury group were respectively (0.084±0.013), (0.115±0.015), (0.158±0.022), (0.099±0.011), (0.099±0.012), (0.089±0.011), (0.124±0.014), and (0.116±0.018) µg/mL, (0.064±0.033), (0.114±0.016), (0.135±0.009), (0.060±0.008), (0.104±0.010), (0.124±0.020), (0.180±0.036), and (0.201±0.032) µg/mL, (0.074±0.013), (0.084±0.035), (0.101±0.050), (0.091±0.046), (0.096±0.034), (0.044±0.019), (0.106±0.049), and (0.118±0.047) µg/mL. Compared with that of rats in sham injury group, D-dimer level significantly decreased at PIH 6 and 12 and significantly increased from PIH 48 to PID 7 ( <0.05 or <0.01). Compared with that of rats in pure burn-blast combined injury group, D-dimer level of rats in ulinastatin+ burn-blast combined injury group significantly decreased at PIH 3, 48, and 72, and on PID 7 ( <0.05 or <0.01). (2) At PIH 24, there was a large amount of light red effusion in the thoracic cavity, and both lung lobes were hyperemic and edematous with a small amount of blood clots in the left and middle lobe of rats in pure burn-blast combined injury group. There was a small amount of yellowish effusion in the thoracic cavity of rats in ulinastatin+ burn-blast combined injury group, and the degree of hyperemic and edematous of bilateral lobes was lighter compared with rats in pure burn-blast combined injury group with no clot in the left lobe. No congestion, edema, or bleeding was observed in lungs of rats in sham injury group. (3) At PIH 72, disorganized alveolar structure, collapsed alveolar cavity, edematous and thickening pulmonary interstitium, infiltration of a large amount of inflammatory cells, obvious rupture of alveolar septum, and hyaline thrombus were observed in lungs of rats in pure burn-blast combined injury group. Significantly improved alveolar structure, less collapsed alveolar cavity, improved edematous pulmonary interstitium, less infiltration of inflammatory cells, rupture of alveolar septum, and no thrombus were observed in lungs of rats in ulinastatin+ burn-blast combined injury group. The lung tissue had a well-filled alveolar cavity with no interstitial edema or infiltration of inflammatory cells and no thrombosis in lungs of rats in sham injury group. Ulinastatin has positive therapeutic effects on acute lung injury in rats with severe burn-blast combined injuries through its good regulating effects on coagulation and fibrinolytic disorders caused by burn-blast combined injuries.
[Mh] Termos MeSH primário: Lesão Pulmonar Aguda/tratamento farmacológico
Traumatismos por Explosões/complicações
Queimaduras/complicações
Glicoproteínas/farmacologia
Inibidores da Tripsina/farmacologia
[Mh] Termos MeSH secundário: Lesão Pulmonar Aguda/complicações
Animais
Traumatismos por Explosões/sangue
Traumatismos por Explosões/patologia
Queimaduras/sangue
Queimaduras/patologia
Edema
Produtos de Degradação da Fibrina e do Fibrinogênio
Edema Pulmonar
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fibrin Fibrinogen Degradation Products); 0 (Glycoproteins); 0 (Trypsin Inhibitors); 0 (fibrin fragment D); OR3S9IF86U (urinastatin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.1009-2587.2018.01.007


  3 / 7701 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29450510
[Au] Autor:Kline JA
[Ad] Endereço:Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis.
[Ti] Título:Utility of a Clinical Prediction Rule to Exclude Pulmonary Embolism Among Low-Risk Emergency Department Patients: Reason to PERC Up.
[So] Source:JAMA;319(6):551-553, 2018 02 13.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Técnicas de Apoio para a Decisão
Embolia Pulmonar
[Mh] Termos MeSH secundário: Serviço Hospitalar de Emergência
Produtos de Degradação da Fibrina e do Fibrinogênio
Seres Humanos
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Nm] Nome de substância:
0 (Fibrin Fibrinogen Degradation Products)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180217
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.21901


  4 / 7701 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29309105
[Au] Autor:Koracevic G; Antonijevic N; Cosic V; Pavlovic M; Kostic T; Zdravkovic M; Cvetkovic T; Tomasevic M; Ciric-Zdravkovic S; Krstic N; Damjanovic M
[Ti] Título:Biomarkers in aortic dissection, including specific causes of troponin elevation.
[So] Source:Vojnosanit Pregl;73(4):368-75, 2016 Apr.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Mh] Termos MeSH primário: Aneurisma Dissecante/diagnóstico
Troponina C/sangue
[Mh] Termos MeSH secundário: Aneurisma Dissecante/sangue
Aneurisma Dissecante/complicações
Biomarcadores
Proteína C-Reativa/análise
Produtos de Degradação da Fibrina e do Fibrinogênio/análise
Seres Humanos
Infarto do Miocárdio/diagnóstico
Infarto do Miocárdio/etiologia
Prognóstico
Acidente Vascular Cerebral/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers); 0 (Fibrin Fibrinogen Degradation Products); 0 (Troponin C); 0 (fibrin fragment D); 9007-41-4 (C-Reactive Protein)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180109
[St] Status:MEDLINE
[do] DOI:10.2298/VSP131211017K


  5 / 7701 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29226714
[Au] Autor:Jákó J
[Ad] Endereço:Budapest, Oltvány u. 28., 1112.
[Ti] Título:[Analysis of D-dimer laboratory findings and clinical evaluation].
[Ti] Título:A D-dimer laboratóriumi eredményeinek és klinikai értékelésének elemzése..
[So] Source:Orv Hetil;158(50):1971-1976, 2017 Dec.
[Is] ISSN:0030-6002
[Cp] País de publicação:Hungary
[La] Idioma:hun
[Ab] Resumo:D-dimer is a product of the enzymatic degradation of the fibrinogen-fibrin molecule, and its existence is demonstrable in circulation. The test based limits may be considered as normal values. It was first thought to be a product of coagulation, then a product of lysis. High-concentration D-dimer in blood detected in thromboembolic diseases is considered to be of diagnostic value. In cases where thromboembolism was ruled out despite elevated titres but heparin (LMWH) or CLOPIDOGREL was given as a cautionary measure, we found that D-dimer values remained elevated. This finding means that in vivo coagulation is not a precondition to D-dimer formation. Analysis of such cases uncovers liver or kidney disease in the background, but old age may also be a factor. Often elevated ferritin levels were observed 'in parallel' with elevated D-dimer values. These findings lead us to presume an enzymatic degradation process of 'elderly' protein molecules, which is universally applicable. Orv Hetil. 2017; 158(50): 1971-1976.
[Mh] Termos MeSH primário: Produtos de Degradação da Fibrina e do Fibrinogênio/análise
Tromboembolia/sangue
[Mh] Termos MeSH secundário: Biomarcadores/sangue
Coagulação Sanguínea
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Fibrin Fibrinogen Degradation Products); 0 (fibrin fragment D)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.1556/650.2017.30909


  6 / 7701 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381980
[Au] Autor:Zhang B; Liu G; Liu X; Zheng S; Dong K; Dong R
[Ad] Endereço:Children's Hospital of Fudan University.
[Ti] Título:Circulating D-dimer level correlates with disease characteristics in hepatoblastoma patients.
[So] Source:Medicine (Baltimore);96(47):e8798, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Hepatoblastoma (HB) is the most common pediatric liver malignancy, typically affecting children within the first 4 years of life. However, only a few validated blood biomarkers are used in clinical evaluation. The current study explored the clinical application and significance of D-dimer levels in patients with HB. METHOD: Forty-four patients with HB were included in this retrospective study. D-dimer and plasma fibrinogen levels were examined, and their correlation with other clinical features was analyzed. D-dimer and plasma fibrinogen levels were examined between HB and other benign hepatic tumors. RESULTS: D-dimer levels were significantly associated with high-risk HB features, such as advanced stage and high α-fetoprotein (AFP) levels. Higher D-dimer levels were observed in stage 4 patients compared with stage 1/2/3 patients (P = .028). Higher D-dimer levels were also observed in patients with higher AFP levels before chemotherapy compared with patients with lower AFP levels after chemotherapy (P< 0.001). In addition, higher D-dimer levels were observed in HB compared with other benign hepatic tumors such as hepatic hemangioma and hepatocellular adenoma (P = .012). No significant difference in D-dimer levels was found between sex (P = .503) and age (≥12 vs <12 months, P = .424). There was no significant difference in plasma fibrinogen levels between sex or age and high-risk HB features, such as advanced stage and high AFP levels. CONCLUSIONS: Elevated D-dimer levels could be a useful determinant biomarker for high-risk features in patients with HB. This finding also supports the clinical application of D-dimer in HB.
[Mh] Termos MeSH primário: Produtos de Degradação da Fibrina e do Fibrinogênio/análise
Hepatoblastoma/sangue
Neoplasias Hepáticas/sangue
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/sangue
Criança
Pré-Escolar
Feminino
Fibrinogênio/análise
Seres Humanos
Lactente
Recém-Nascido
Masculino
Estudos Retrospectivos
alfa-Fetoproteínas/análise
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Fibrin Fibrinogen Degradation Products); 0 (alpha-Fetoproteins); 0 (fibrin fragment D); 9001-32-5 (Fibrinogen)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008798


  7 / 7701 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29279528
[Au] Autor:Wang Z; Qian Z; Ren J; Men J; Wen J; Wei M
[Ad] Endereço:Department of Cardiac Surgery, Shenzhen Sun Yat-sen Cardiovascular Hospital.
[Ti] Título:Long Period and High Level of D-Dimer after Coronary Artery Bypass Grafting Surgery.
[So] Source:Int Heart J;59(1):51-57, 2018 Jan 27.
[Is] ISSN:1349-3299
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Hyper-coagulation after off-pump coronary artery bypass grafting (OPCAB) is one of the main reasons for graft thrombosis. D-dimer is closely linked to the activation of coagulation. Few studies have reported the variation range and long-term abnormal coagulation after OPCAB in the Chinese population. Our study aimed to determine the characteristics and value of D-dimer after OPCAB.In this prospective study, 265 patients who underwent OPCAB for the first time were recruited from 2011 to 2012. The D-dimer level of the patients was tested before surgery and on the 1st, 4th, and 14th day, and 1st, 2nd, and 3rd month after surgery. Clinical data in the perioperative period and during the one-year follow-up period were recorded.D-dimer level increased from day 4 after OPCAB ([1321.9 ± 36.4] µg/L), peaked at 1 month ([2839.7 ± 101.4] µg/L), and decreased to the baseline ([370.3 ± 260.2] µg/L) 3 months after surgery. No death occurred, but 25 (10%) patients suffered recurrent angina in the one-year follow-up. They had significantly higher D-dimer level at one month after OPCAB than those of patients who did not suffer from angina. Preoperative ejection fraction <50% and D-dimer level >2915 µg/L at one month after surgery were significantly associated the recurrent angina.After OPCAB, patients have a higher level of D-dimer. And this lasts for a long period (about 3 months). It may reflect a certain degree of hypercoagulable and hyperfibrinolytic state after OPCAB.
[Mh] Termos MeSH primário: Coagulação Sanguínea/fisiologia
Ponte de Artéria Coronária sem Circulação Extracorpórea/efeitos adversos
Doença da Artéria Coronariana/cirurgia
Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo
Complicações Pós-Operatórias
Trombofilia/sangue
[Mh] Termos MeSH secundário: Biomarcadores/sangue
China/epidemiologia
Feminino
Seguimentos
Seres Humanos
Incidência
Masculino
Meia-Idade
Estudos Prospectivos
Trombofilia/complicações
Trombofilia/epidemiologia
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Biomarkers); 0 (Fibrin Fibrinogen Degradation Products); 0 (fibrin fragment D)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1536/ihj.16-595


  8 / 7701 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463882
[Au] Autor:Kim CJ; Rousseau R; Huibner S; Kovacs C; Benko E; Shahabi K; Kandel G; Ostrowski M; Kaul R
[Ad] Endereço:aUniversity Health Network bDepartments of Medicine and Immunology, University of Toronto cMaple Leaf Medical Clinic dSt. Michael's Hospital, Toronto, Ontario, Canada.
[Ti] Título:Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers.
[So] Source:AIDS;31(11):1529-1534, 2017 Jul 17.
[Is] ISSN:1473-5571
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Standard antiretroviral therapy (ART) is slow to reverse gut mucosal immune defects that cause persistent inflammation and immune activation. We examined whether intensifying early-administered ART through the addition of maraviroc and raltegravir would accelerate their resolution. DESIGN: ART-naïve men with early HIV infection were randomized in a double-blind manner to receive ART (emtricitabine/tenofovir disoproxil fumarate + lopinavir/ritonavir), together with either combined placebo or raltegravir + maraviroc, for 48 weeks. In a predefined substudy, paired blood and sigmoid biopsies were collected at baseline and week 48. Mucosal CD4 T-cell immune subsets (Th1, Th17, and Th22 cells), CD8 T-cell immune activation, and soluble blood markers of inflammation (IL-6, IL-17, macrophage inflammatory protein-1b, soluble CD14, and IL-10) and coagulation (D-dimer) were measured. RESULTS: A total of 22 participants were enrolled, a median of 4 months after HIV acquisition. At baseline, there was substantial systemic and mucosal immune activation, and gut CD4 T-cell numbers, Th22 cell numbers, and Th17 cell function were reduced compared with controls. Early ART restored gut Th22 numbers, improved but did not restore overall CD4 numbers, and had no impact on Th17 function. Plasma levels of soluble CD14 and D-dimer normalized, whereas other inflammatory cytokines were reduced but not normalized. ART intensification had no impact on any blood or gut immune parameters. CONCLUSION: Early HIV infection causes substantial mucosal and systemic immune activation, and gut CD4 T-cell dysfunction. One year of ART improved but did not normalize most parameters, regardless of intensification with raltegravir and maraviroc, and did not restore mucosal Th17 function.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/farmacologia
Infecções por HIV/tratamento farmacológico
Imunidade nas Mucosas/efeitos dos fármacos
Inflamação/sangue
Inflamação/tratamento farmacológico
Mucosa Intestinal/efeitos dos fármacos
Mucosa Intestinal/imunologia
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/sangue
Canadá
Cicloexanos/farmacologia
Método Duplo-Cego
Quimioterapia Combinada
Produtos de Degradação da Fibrina e do Fibrinogênio/efeitos dos fármacos
Citometria de Fluxo
Infecções por HIV/sangue
Infecções por HIV/imunologia
Seres Humanos
Inflamação/imunologia
Ativação Linfocitária/efeitos dos fármacos
Masculino
Meia-Idade
Estudos Prospectivos
Raltegravir Potássico/farmacologia
Células Th17/efeitos dos fármacos
Resultado do Tratamento
Triazóis/farmacologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (Biomarkers); 0 (Cyclohexanes); 0 (Fibrin Fibrinogen Degradation Products); 0 (Triazoles); 0 (fibrin fragment D); 43Y000U234 (Raltegravir Potassium); MD6P741W8A (maraviroc)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM; X
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1097/QAD.0000000000001515


  9 / 7701 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29235323
[Au] Autor:Grinenko TV; Kapustianenko LG; Yatsenko TA; Yusova OI; Rybachuk VN
[Ti] Título:Plasminogen fragments K 1-3 and K 5 bind to different sites in fibrin fragment DD.
[So] Source:Ukr Biochem J;88(3):36-45, 2016 May-Jun.
[Is] ISSN:2409-4943
[Cp] País de publicação:Ukraine
[La] Idioma:eng
[Ab] Resumo:Specific plasminogen-binding sites of fibrin molecule are located in Аα148-160 regions of C-terminal domains. Plasminogen interaction with these sites initiates the activation process of proenzyme and subsequent fibrin lysis. In this study we investigated the binding of plasminogen fragments K 1-3 and K 5 with fibrin fragment DD and their effect on Glu-plasminogen interaction with DD. It was shown that the level of Glu-plasminogen binding to fibrin fragment DD is decreased by 50-60% in the presence of K 1-3 and K 5. Fragments K 1-3 and K 5 have high affinity to fibrin fragment DD (Kd is 0.02 for K 1-3 and 0.054 µÐœ for K 5). K 5 interaction is independent and K 1-3 is partly dependent on C-terminal lysine residues. K 1-3 interacts with complex of fragment DD-immobilized K 5 as well as K 5 with complex of fragment DD-immobilized K 1-3. The plasminogen fragments do not displace each other from binding sites located in fibrin fragment DD, but can compete for the interaction. The results indicate that fibrin fragment DD contains different binding sites for plasminogen kringle fragments K 1-3 and K 5, which can be located close to each other. The role of amino acid residues of fibrin molecule Аα148-160 region in interaction with fragments K 1-3 and K 5 is discussed.
[Mh] Termos MeSH primário: Produtos de Degradação da Fibrina e do Fibrinogênio/química
Fibrinogênio/química
Fragmentos de Peptídeos/química
Plasminogênio/química
[Mh] Termos MeSH secundário: Sítios de Ligação
Ligação Competitiva
Biotinilação
Seres Humanos
Cinética
Ligação Proteica
Domínios e Motivos de Interação entre Proteínas
Proteólise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fibrin Fibrinogen Degradation Products); 0 (Peptide Fragments); 0 (fibrin fragment D); 9001-32-5 (Fibrinogen); 9001-91-6 (Plasminogen)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE
[do] DOI:10.15407/ubj88.03.036


  10 / 7701 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29227605
[Au] Autor:Pyrogova LV; Chernyshenko TM; Kolesnikova IN; Platonova TN; Bereznitsky GK; Makogonenko YM; Lugovskoy EV
[Ti] Título:Level of overall hemostasis potential in donor and patient plasma in pathology.
[So] Source:Ukr Biochem J;88(2):56-65, 2016 Mar-Apr.
[Is] ISSN:2409-4943
[Cp] País de publicação:Ukraine
[La] Idioma:eng
[Ab] Resumo:Coagulation potential (CP), overall hemostasis potential (OHP) and fibrinolysis potential (FP) in plasma of donors and patients with myocardial infarction (MI), stroke (St) and hip joint diseases (HJD) have been investigated using M. Blomback's global hemostasis assay. Plasma samples of the patients were analyzed with APTT reagent in the presence or absence of t-PA. It was found that the ratio of values of СP, OHP and FP in plasma of patients to those of donors plasma were 78, 60 and 123% at MI; 157, 155 and 162% at St; 128, 131 and 124% at HJD. CP to FP ratio that indicated balance between coagulation and fibrinolytic systems activities were 4.13, 2.5, 4.0 and 4.26 in plasma of donors and MI, St and HJD patients, respectively. These results are evidence of increased fibrinolytic activity in plasma of MI patients. Lag-periods of plasma clotting of MI, St and HJD patients were prolonged by 2.3, 7.2 and 1.5-fold, respectively. Pearson's correlation analysis between parameters, obtained in vitro studies using global hemostasis assay, and concentrations of the molecular markers (soluble fibrin and D-dimer), which formed in vivo in plasma of MI, St and HJD patients, did not reveal any relationship between them.
[Mh] Termos MeSH primário: Artrite Reumatoide/sangue
Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo
Fibrina/metabolismo
Hemostasia/fisiologia
Infarto do Miocárdio/sangue
Acidente Vascular Cerebral/sangue
[Mh] Termos MeSH secundário: Idoso
Artrite Reumatoide/patologia
Biomarcadores/sangue
Estudos de Casos e Controles
Feminino
Seres Humanos
Masculino
Infarto do Miocárdio/patologia
Acidente Vascular Cerebral/patologia
Ativador de Plasminogênio Tecidual/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Fibrin Fibrinogen Degradation Products); 0 (fibrin fragment D); 9001-31-4 (Fibrin); EC 3.4.21.68 (PLAT protein, human); EC 3.4.21.68 (Tissue Plasminogen Activator)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.15407/ubj88.02.056



página 1 de 771 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde